Most people are aware of type 1 and type 2 diabetes, but did you know there is a type 3 diabetes as well! It is a more obscure term. Although it is not an accepted medical diagnosis, type 3 diabetes has been discussed in the literature as a possible relationship between insulin resistance in the brain and Alzheimer's disease. This link has been described to help explain how metabolic disorders impact brain health, causing cognitive decline and dementia.

What is Type 3 Diabetes?

Type 3 diabetes is more of a misnomer because it should not be confused with type 3c diabetes, which relates to pancreatic dysfunction. The term "type 3 diabetes," on the other hand, has been loosely used by some scientists to analogously propose that Alzheimer's disease is strongly implicated with insulin resistance in the brain.

This concept was conceptualized by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University in the year 2008. This hypothesis postulated that Alzheimer's disease may be called type 3 diabetes for it bears many similarities with glucose metabolism disorder type 2 diabetes. Their concept arises from the basic principle that insulin is fundamental to blood sugar regulation, but it is also the case with the brain. When brain cells become insulin-resistant, they lose access to glucose, impairing their function.

Research published in the Journal of Diabetes Science and Technology supports this hypothesis by indicating that insulin resistance can be a significant contributor to the occurrence of dementia, also referred to as Alzheimer's. The symptoms of memory loss and diminished reasoning are associated with impaired glucose metabolism in the body, especially in the cerebral tissue.

Symptoms of Type 3 Diabetes

Although type 3 diabetes is not a "medical term," its symptoms correlate well with Alzheimer's diseases that are known to reduce the ability to think in an efficient manner and bring down brain health. These signs are:

- Loss of memory, especially short-term.

- Poor judgment and judgment ability

- Failure in recognizing people or places familiar once.

- Failure in the process of reading, writing or processing numbers

- Anxiety, agitation, or mood changes.

- Disorganized thoughts or confusion

- Lack of impulse control

As the disease advances, patients may be afflicted with severe complications including an inability to swallow or control their bodily functions. In the final stages, most patients die from fatal complications such as aspiration pneumonia.

Causes of Type 3 Diabetes

This may not be well understood with regards to type 3 diabetes, or the exact link between insulin resistance and Alzheimer's disease. Some identified contributing factors include the following:

1. Insulin Resistance

Insulin acts as an important regulatory mechanism of brain functions such as memory and cognition. The reduction in insulin signaling may impair metabolism of brain cells, thus bringing about neurodegeneration.

2. Type 2 Diabetes

These diseases show a strong relationship and those individuals diagnosed with type 2 diabetes have double chances of getting Alzheimer's. In the two, the main causes can be chronic inflammation, oxidative stress, and a defect in glucose metabolism.

3. Environmental and Lifestyle Factors

Insulin resistance associated with obesity, stress, and an unhealthy diet is considered a cause that may increase the chances of Alzheimer's disease.

Researches in Frontiers in Neuroscience and The Lancet Neurology have also highlighted that drugs used for antidiabetic medication may be crucial for the prevention or at least slowing down the course of Alzheimer's.

Treatments for Type 3 Diabetes

In 2022, in a study in Pharmaceuticals, researchers studied biomarker uptake in brain regions implicated in the faulty uptake and metabolism of blood sugar in Alzheimer’s patients.

Emerging Therapies

Research into such treatments as intranasal insulin has also been promising. Intranasal delivery of insulin directly to the brain has been reported to enhance glucose uptake by brain cells, improve memory, and boost cognitive performance. While such clinical trials have been shown to be successful, additional research is needed for safety and efficacy.

Medications

For patients being aggressive or agitated, antipsychotic drugs may be prescribed; however, therapies such as cognitive rehabilitation as well as cognitive stimulation therapy serve to preserve memory and executive function.

Lifestyle Interventions

Diet, exercise, and stress management are critical in preventing and managing insulin resistance. A review in the Journal of Alzheimer's Disease also highlighted the benefits of Kirtan Kriya meditation, which can regulate genes involved in insulin and glucose metabolism, improve sleep, and reduce inflammation.

Can Type 3 Diabetes Be Prevented?

Although type 3 diabetes is not officially recognized, its connection to Alzheimer’s disease underscores the importance of proactive measures for brain health. Some prevention strategies include:

1. Healthy Diet

Consuming a balanced diet rich in antioxidants, whole grains, and healthy fats may support brain health.

2. Regular Exercise

Physical activity improves insulin sensitivity, reduces inflammation, and enhances overall metabolic health.

3. Stress Reduction

Mindfulness practices, including meditation, have been shown to lower stress levels, which can reduce the risk of cognitive decline.

The term type 3 diabetes brings out the complex relationship between metabolic disorders and brain health. Even though it is not a recognized medical condition, the concept emphasizes the crucial role of insulin in brain function and its possible contribution to Alzheimer's disease. Continued research will hopefully provide hope for therapies such as intranasal insulin and lifestyle modifications.

As artificial intelligence becomes a go-to source for quick answers, a new University of Oxford-led study on AI chatbots and medical advice is raising serious concerns about how safe it is to rely on these tools for health guidance.

The research suggests that while AI chatbots can provide medical information, their advice is often inaccurate, inconsistent, and difficult for users to interpret, potentially putting people at risk—especially when dealing with symptoms that need urgent care.

What the Oxford Study Found

The study involved 1,300 participants who were given realistic health scenarios, such as experiencing a severe headache or being a new mother feeling constantly exhausted. Participants were divided into two groups: one group used AI chatbots to understand their symptoms and decide next steps, while the other did not.

Researchers then assessed whether participants correctly identified what might be wrong and whether they made appropriate decisions, such as seeing a GP or visiting A&E.

The results were troubling. People who relied on AI frequently failed to identify the severity of their condition and were often unsure about when to seek professional medical help.

Why Chatbot Advice Can Go Wrong

According to the researchers, one major issue is that people don’t always know what to ask. The study found that chatbot responses varied widely depending on how questions were phrased. Even small changes in wording could lead to completely different answers.

The AI often produced a mix of helpful and misleading information, leaving users to decide which advice mattered. Many participants struggled to distinguish between reliable guidance and unnecessary or confusing details.

As one of the study’s authors explained, when an AI lists multiple possible conditions, users are left guessing which one applies to them—precisely the moment where mistakes can happen.

A Dangerous Gap in Symptom Interpretation

Dr Rebecca Payne, lead medical practitioner on the study, warned that asking chatbots about symptoms could be “dangerous”, particularly when users delay seeking professional care based on AI responses.

Dr Adam Mahdi, the study’s senior author, noted that while AI can share medical facts, people often share information gradually and leave out key details—something chatbots struggle to manage effectively.

Bias, Data, and the Limits of AI

Experts also point out that chatbots are trained on existing medical data, which means they may repeat long-standing biases baked into healthcare systems. As one psychiatry expert put it, a chatbot is only as accurate as human clinicians—and humans are far from perfect.

That said, not everyone is pessimistic.

What Comes Next for AI in Healthcare

Digital health experts argue the technology is evolving. Health-specific versions of general AI chatbots have recently been released by major developers, and these could perform differently in future studies.

The consensus among experts is clear: AI in healthcare should focus on improvement, regulation, and guardrails, not replacement of doctors. Used responsibly, it may support healthcare—but without safeguards, it risks doing more harm than good.

This common pregnancy drug could be linked to cancer. Wes Streeting has been urged to launch a public inquiry into a miscarriage drug called Diethylstilbestrol, which, reports say has "ruined and devastated" the lives of countless women. On Monday, the Health Secretary Streeting met victims of the pregnancy drugs, which has been linked to cancer, early menopause and infertility.

What Is Diethylstilbestrol?

Diethylstilbestrol, commonly known as DES, is a synthetic form of female hormone estrogen, which was prescribed to thousands of pregnant women from 1940 to 1970s.

The drug was used to prevent miscarriage, premature labor and complications of pregnancy. This was also used to suppress breast milk production, as an emergency contraception and to treat symptoms of menopause.

What Is The DES Controversy?

In 1971, Diethylstilbestrol (DES) was linked to a rare cancer of the cervix and vagina known as clear cell adenocarcinoma, prompting US regulators to advise that it should no longer be prescribed to pregnant women. Despite this, the drug continued to be given to expectant mothers across parts of Europe until 1978. DES has also since been associated with other cancers, including breast, pancreatic and cervical cancers, The Telegraph reported.

Campaign group DES Justice UK (DJUK) is now urging Health Secretary Wes Streeting to order a public inquiry and introduce an NHS screening programme to identify people who may have been exposed to the drug before birth.

Victims described DES as “one of the biggest pharmaceutical scandals this country has ever seen,” warning that “the impact of this terrible drug cannot be underestimated as it has ruined and devastated so many lives,” according to The Telegraph.

In November, Streeting acknowledged that the “state got it wrong” and issued an apology to those affected. He also advised anyone who believes they may have been exposed to DES to speak to their GP.

Susie Martin, 55, from Manchester, whose mother was prescribed DES during pregnancy, told The Telegraph she has undergone between 20 and 30 operations as a result of the drug’s effects.

“The impact of this terrible drug cannot be underestimated as it has ruined and devastated so many lives, including my own,” she said. “The physical and emotional pain has been unbearable. I live with a constant fear that I will need more surgery or develop cancer—and I am far from the only one.”

Calling DES a “silent scandal,” Martin said she hopes the government’s engagement will lead to concrete action. “While I welcome Mr Streeting meeting us, it will only matter if he commits to meaningful steps for victims of this shameful chapter in British medical history, including a screening programme and a full statutory public inquiry,” she added.

What Is Happening With The DES Victims?

The Telegraph reported that compensation schemes have been set up for DES victims in the US and Netherlands, however, UK does not have one yet.

"There are harrowing accounts of harm caused by the historic use of Diethylstilbestrol (DES). Some women and their relatives are still suffering from the associated risks of this medicine which have been passed down a generation, and haven’t been supported. The Secretary of State has been looking seriously at this legacy issue and carefully considering what more the government can do to better support women and their families who have been impacted. NHS England has alerted all cancer alliances to this issue so that healthcare professionals are aware of the impacts of DES and the existing NHS screening guidance which sets out the arrangements for those who show signs and symptoms of exposure,” said a Department of Health and Social Care spokesman to The Telegraph.

The World Health Organization (WHO)'s Montreal meeting focused on wearable technology like smartwatches and activity trackers as a reliable source of health tracking. The meeting discussed that wearables could in fact generate objective real-time data, which helps governments design targeted and evidence-based health interventions.

Physicians in the Montreal meetings discussed that wrist-worn devices are more reliable than traditional self-reported surveys. This is because the self-reported surveys could underestimate the levels of physical inactivity.

“Metrics such as step count, moderate-to-vigorous physical activity and sedentary time directly correlate with cardiovascular disease, diabetes and mental health outcomes. Having population-level data allows for early and preventive strategies,” said Dr Venkat Nani Kumar, consultant in internal medicine.

WHO Montreal Meeting: How Have Doctors Reacted The Shift To Wearables?

Doctors in India have welcomed this shift to wearable devices as a better way to generate data and make policies. Dr Kiran Madhala, professor at Gandhi Medical College, Secunderabad, said WHO’s shift reflects rapid advances in artificial intelligence and digital health tools, calling it a progressive step towards improved monitoring of physical activity worldwide.

City-based doctors also underlined the need for inclusive validation of devices. “Wearables must recognise varied movement patterns and step equivalents, especially in ageing populations,” a physician said, while stressing the importance of data privacy and ethical use of health information.

WHO Montreal Meeting: What Are Wearable Health Devices?

As per a 2022 study published in JMIR MHealth and UHealth, wearables refer to devices that are worn by individuals. In health care field, they assist with individual monitoring and diagnosis. Wearables are “seamlessly embedded portable computers...worn on the body," notes another 2018 study published in Telematics Informatics.

A 2018 study published in the journal Sensors noted that wearable health devices are increasingly helping people to better monitor their health status both at an activity/fitness level for self health tracking and at a medical level providing more data to clinicians with a potential for earlier diagnostic and guidance of treatment.

WHO Montreal Meeting: What Are Some Examples Of Wearables?

Blood Pressure Monitor

This is a blood pressure monitor that consists of a cuff that is placed in upper arm with a digital display that provides real time reading of systolic and diastolic blood pressure.

Glucose Monitoring Device

This device estimates your glucose levels in every few minutes. It can be worn in upper arm, with a phone sensor connected to measure readings. It also includes real time glucose alarms to make informed decisions.

Wearable ECG Monitor

ECG patches are interconnected with smartphones, where one can see their readings. They not only measure electrocardiograms, but also detect any abnormalities.

Fitness Tracker

Smartwatches or fitbits that could be worn on your wrist. They help track real time data of your health, steps, heart rate, calorie consumptions, and even sleep patterns. It can also help keep track of oxygen levels.

Integrated Activewear

These activewears come with microscopic sensors to safeguard wearer's body or assist them in reaching their fitness objective.